Home   ->   news   ->   Press Releases

Press Releases

WuXi PharmaTech Broadens its Trademark Protection

August 21, Shanghai, China - WuXi PharmaTech—a leading provider of pharmaceutical R&D services in China announced today that it has obtained two additional trademark registration certificates—"Yao Ming Kang De" (Class 40), the Chinese name for WuXi PharmaTech, and " " (Class 40) issued by the Chinese Trademark Office. This follows two trademark registration certificates, "Yao Ming Kang De"(Class 5) and " "(Class 5), obtained in June, 2006. [1]

In order to better protect the identity of the company, service portfolio, and the rights of its customers, WuXi PharmaTech applied in 2003 for trademark registration of both the Chinese and English company name.

"Intellectual property is a pharmaceutical company's most valuable asset, and IP protection is essential to the success of China's pharmaceutical and pharmaceutical outsourcing industry. As a strict defender of IP rights, WuXi PharmaTech continues to strive to protect its partners by persistently raising the bar for IP standards in China."said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech.

[1] CLASS 5 (Pharmaceuticals), Pertains to pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. This class includes mainly pharmaceuticals and other preparations for medical purposes.

CLASS 40 (Treatment of materials), This class includes mainly services not included in other classes, rendered by the mechanical or chemical processing or transformation of objects or inorganic or organic substances.

About WuXi PharmaTech (Cayman) Inc.
WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec. For more information, please visit: www.wuxiapptec.com.

back to top